[{"id":"c96af201-1fe0-41f1-9d48-5df4a19900bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03919526","created_at":"2021-01-18T19:17:14.730Z","updated_at":"2024-07-02T16:35:26.713Z","phase":"Phase 1","brief_title":"Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL","source_id_and_acronym":"NCT03919526","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" CD22","pipe":" | ","alterations":" CD19 positive • CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • anti-CD19/CD22 CAR-T cells"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/11/2019","start_date":" 08/11/2019","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-12-08"},{"id":"44d6ee40-9949-4f9b-a8b2-d03e278824b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05651178","created_at":"2022-12-14T14:58:25.758Z","updated_at":"2024-07-02T16:35:59.150Z","phase":"Phase 1","brief_title":"Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients","source_id_and_acronym":"NCT05651178","lead_sponsor":"Hrain Biotechnology Co., Ltd.","biomarkers":" IL6 • CD22 • IL15","pipe":" | ","alterations":" CD22 positive","tags":["IL6 • CD22 • IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-CD19/CD22 CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/12/2022","start_date":" 08/12/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2022-12-14"},{"id":"09371def-48fc-484c-8294-7f123fc8e304","acronym":"","url":"https://clinicaltrials.gov/study/NCT05223686","created_at":"2022-02-05T18:29:33.583Z","updated_at":"2024-07-02T16:36:17.576Z","phase":"Phase 1","brief_title":"To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.","source_id_and_acronym":"NCT05223686","lead_sponsor":"Hrain Biotechnology Co., Ltd.","biomarkers":" IL6 • CD22 • IL15","pipe":" | ","alterations":" CD22 positive","tags":["IL6 • CD22 • IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-CD19/CD22 CAR-T cells"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/10/2022","start_date":" 02/10/2022","primary_txt":" Primary completion: 06/10/2023","primary_completion_date":" 06/10/2023","study_txt":" Completion: 03/10/2025","study_completion_date":" 03/10/2025","last_update_posted":"2022-02-04"}]